Quantcast

Latest Generic drug Stories

2014-07-24 23:02:33

New comprehensive report “Memantine - Comprehensive patent search” elaborated by Ark Patent Intelligence is now available at MarketPublishers.com. London, UK (PRWEB) July 24, 2014 Memantine was initially developed by Merz to treat Alzheimer’s disease (AD) and was first marketed in Germany under the brand name Akatinol; it was later licensed to Lundbeck Ltd. in Europe and other nations as Ebixa and in the USA to Forest Labs as Namenda. Lundbeck reported the sales of Ebixa of USD 420...

2014-07-24 08:33:04

SAN DIEGO, July 24, 2014 /PRNewswire/ -- MedVantx, Inc., the company that has built an innovative new direct-to-consumer prescription delivery channel in physician offices, MedStart Connect, today announced it eliminates many of the underlying issues related to medication non-adherence and hospital readmission rates specified in a study published in a recent issue of the Annals of Internal Medicine. In the study, researchers reported that frequent changes in generic medication pill...

2014-07-23 12:31:16

Study quantifies lost savings from REMS and related restricted access tactics WASHINGTON, July 23, 2014 /PRNewswire-iReach/ -- Use of Risk Evaluation and Mitigation Strategies (REMS) and other restricted access programs to delay generic market entry results in $5.4 billion in lost savings annually, according to a new survey and analysis by economic consulting firm Matrix Global Advisors (MGA). Logo - http://photos.prnewswire.com/prnh/20140723/129680 Required by the Food and Drug...

2014-07-21 16:26:17

SAN FRANCISCO and DUBLIN, July 21, 2014 /PRNewswire/ -- Medicines360, a non-profit women's health pharmaceutical company, and Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Medicines360's New Drug Application (NDA) for Levosert(TM) (levonorgestrel), a hormonal intrauterine contraceptive (IUC) for use by women to prevent pregnancy. In June 2013, Medicines360 and...

2014-07-17 04:20:56

GENEVA, July 17, 2014 /PRNewswire/ -- MPP forges first agreement with a Chinese manufacturer Desano; and with Cipla, Mylan and Micro Labs; Extends Collaborations with Aurobindo, Laurus Labs and Emcure Three days before the start of the 20th International AIDS Conference in Melbourne, Australia, the Medicines Patent Pool (MPP) announced seven new sub-licensing agreements for the manufacture of generic HIV medicines, atazanavir (ATV) and dolutegravir (DTG). The...

2014-07-15 23:12:37

As industry evolves, Model N Inc.’s proven and established solution for generics manufacturers continues to attract global leaders. Redwood Shores, CA (PRWEB) July 15, 2014 Model N, Inc. (NYSE: MODN), the leading revenue management solutions provider to the life science and technology industries, and Ranbaxy Pharmaceuticals Inc. of Jacksonville, Florida announced today that Ranbaxy has selected Model N’s revenue management suite to improve financial controls and gain a more unified...

2014-07-11 16:23:31

DUBLIN, July 11, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-release tablets, 10 mg/10 mg. Actavis' ANDA product is a generic version of Duchesnay Inc.'s Diclegis(®), which is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to...

2014-07-08 16:25:34

DUBLIN, July 8, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dalfampridine Extended-release Tablets, 10 mg. Actavis' ANDA product is a generic version of Acorda Therapeutics' Ampyra(®), which is indicated as a treatment to improve walking in patients with multiple sclerosis. Acorda Therapeutics, Inc. filed suit against Actavis on...

2014-07-08 08:30:07

PITTSBURGH, July 8, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Telmisartan Tablets USP, 20 mg, 40 mg and 80 mg, the generic version of Boehringer Ingelheim's Micardis® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of hypertension, to lower blood pressure. Telmisartan Tablets USP, 20 mg, 40 mg and 80...

2014-07-01 23:08:48

Co-Pay Discount, an app which alerts physicians and consumers about discounts on prescription medications, is calling for an end to ‘pay for delay’ deals between drug companies which are slowing down the entry of cheaper generic drugs onto the market after their patents expire. The physicians behind the discount app, which facilitate discounts for health practitioners and their patients, are speaking out about the deals, which could be preventing people from getting their hands on more...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related